Ausgabe 5/2022
Inhalt (14 Artikel)
Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research
Mireille Langouo Fontsa, Marco Maria Aiello, Edoardo Migliori, Mario Scartozzi, Matteo Lambertini, Karen Willard-Gallo, Cinzia Solinas
Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis
Evangelos Digkas, Anthony Jagri Tabiim, Daniel Smith, Antonis Valachis
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
Ghassan K. Abou-Alfa, Kristen Bibeau, Nikolaus Schultz, Amin Yaqubie, Brittanie Millang, Haobo Ren, Luis Féliz
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma
Jennifer J. Gile, Vanessa Wookey, Tyler J. Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts, Robert R. McWilliams, Wen Wee Ma, Mitesh Borad, Tanios S. Bekaii-Saab, Nguyen H. Tran, Amit Mahipal
Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
Sophie O’Haire, Koen Degeling, Fanny Franchini, Ben Tran, Stephen J Luen, Clara Gaff, Kortnye Smith, Stephen Fox, Jayesh Desai, Maarten IJzerman
Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists
Andrew J Klink, Abhishek Kavati, Awa Gassama, Tom Kozlek, Ajeet Gajra, Ruth Antoine
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
Iris Y. Sheng, Shilpa Gupta, Chandana A. Reddy, Dana Angelini, Pauline Funchain, Tamara A. Sussman, Joseph Sleiman, Moshe C. Ornstein, Keith McCrae, Alok A. Khorana
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
Matteo Santoni, Javier Molina-Cerrillo, Zin W. Myint, Francesco Massari, Tomas Buchler, Sebastiano Buti, Marc R. Matrana, Ugo De Giorgi, Mimma Rizzo, Ignacio Ortego Zabalza, Luca Galli, Paolo Andrea Zucali, Gaetano Aurilio, Lorena Incorvaia, Maria Bassanelli, Giulia Mammone, Alessia Salfi, Luca Isella, Veronica Mollica, Enrique Grande, Camillo Porta, Nicola Battelli
Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
Asuka Sano, Yusuke Inoue, Hirotoshi Kikuchi, Kensuke Fukuchi, Kazuhito Funai, Atsushi Imai, Yuto Matsushita, Keita Tamura, Masatoshi Kitagawa, Hideaki Miyake
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Daniele Lavacchi, Nicola Personeni, Francesca Ratti, Federica Pedica, Angelo Della Corte, Mara Persano, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
Makoto Nishio, Terufumi Kato, Ryo Toyozawa, Toyoaki Hida
Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta‑Analysis
Daqi Jia, Leilei Li, Peng Wang
Author’s Reply to Jia et al.: “BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta‑Analysis”
Francisco Jose Candido dos Reis
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C. Adams III, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed